Molecular Mechanisms of PDE5 Regulation
PDE5 调控的分子机制
基本信息
- 批准号:6736841
- 负责人:
- 金额:$ 32.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-05-01 至 2006-04-30
- 项目状态:已结题
- 来源:
- 关键词:3&apos5&apos cyclic nucleotide phosphodiesteraseX ray crystallographyallosteric siteanimal tissueconformationcyclic GMPenzyme mechanismenzyme structuregene mutationinfrared spectrometrynucleotide analogphosphodiesterase inhibitorsphosphoprotein phosphatasephosphorylationprotein kinaseprotein sequencestructural biologytissue /cell culturevascular smooth muscle
项目摘要
DESCRIPTION (Applicant's abstract): Interest in mammalian cGMP cascades has
recently been intense. Much research in this area has centered on the signal
receptors and guanylyl cyclases that modulate cGMP formation, as well as on
cellular actions of cGMP. Natural signals (natriuretic peptides, guanylins and
nitric oxide), in addition to many medications, stimulate cGMP cascades by
activating these cyclases. Cyclic nucleotide phosphodiesterases (PDEs), which
are also highly modulated enzymes, participate in regulating cellular cAMP and
cGMP levels by catalyzing breakdown of cAMP and cGMP. The subject of this
application is the cGMP-binding cGMP-specific PDE (PDE5), which is specific for
cGMP over cAMP at its allosteric cGMP-binding sites and at its catalytic site.
The long-term goal is to determine the mechanism of action and cellular
regulation of PDE5, a major determinant of cGMP level in many tissues.
Classical effects of cGMP include relaxation of smooth muscle, inhibition of
platelet activation, neutrophil degranulation, and mediation of vision. New
discoveries have expanded this list to include regulation of gene expression,
chloride transport in intestine and kidney, watertransport, bone resorption,
melanogenesis in skin, long-term nerve depression, and opioid effects.
Therapeutic agents that elevate cGMP include PDE inhibitors (e.g., caffeine,
papaverine, and sildenafil) and nitrovasodilators (e.g., nitroglycerin).
Certain enterotoxins cause secretory diarrhea by elevating cGMP. Dr. Corbin
recently demonstrated that in some instances cGMP acts by "crossactivating"
cAMP receptors. However, PDE5 is a specific intracellular receptor for cGMP.
The present proposal represents a thorough biochemical and physiological
investigation of PDE5 regulation. This enzyme is the specific target of
sildenafil (Viagra.), which is used in treatment of male erectile dysfunction
associated with diabetes, aging, spinal cord injuries and other pathologies.
Effects of phosphorylation of PDE5 by cyclic nucleotide-dependent protein
kinases on catalysis and allosteric cGMP binding will be explored, and effects
of mutating the phosphorylation site, Ser- 102 (human), to Ala, Glu, and Asp
will be examined. The principal investigator will study the PDE5 regulatory
domain structure and function by expressing truncation mutants that include
various combinations of the two allosteric cUMP-binding sites and the
phosphorylation site of the enzyme but exclude the catalytic domain. Small
angle x-ray scattering and Fourier transformed infra-red spectroscopy will be
used to study effects of cGMP and phosphorylation on conformation of these
domains. Crystallography of certain truncated regulatory domains will be
attempted. The specificity and efficacy with which phosphoprotein phosphatases
of vascular smooth muscle extracts catalyze dephosphorylation of Ser-102 will
be investigated. Short-term regulation of PDE5 in intact vascular smooth muscle
by cGMP analogs, phosphoprotein phosphatase inhibitors, and agents that elevate
cGMP will be studied. The possibility that these agents could alter enzyme
activity, subcellular localization, or cGMP levels (feedback mechanism) will be
examined. Potential non-covalent modulators of PDE5 other than cGMP will be
sought. The possibility that PDE5 allosteric sites represent a sequestration
site for cGMP in cells will be explored. Results of these studies will provide
a basis for understanding fundamental questions relating to cGMP signaling in
many tissues.
描述(申请人摘要):对哺乳动物cGMP级联的兴趣
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JACKIE David CORBIN其他文献
JACKIE David CORBIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JACKIE David CORBIN', 18)}}的其他基金
9TH INT'L CONFERENCE ON 2ND MESSENGERS & PHOSPHOPROTEINS
关于第二使者的第九届国际会议
- 批准号:
2192995 - 财政年份:1995
- 资助金额:
$ 32.28万 - 项目类别:
9TH INT'L CONFERENCE ON 2ND MESSENGERS & PHOSPHOPROTEINS
关于第二使者的第九届国际会议
- 批准号:
2192996 - 财政年份:1995
- 资助金额:
$ 32.28万 - 项目类别:
FASEB SUMMER RESEARCH CONFERENCE: PROTEIN KINASES
FASEB 夏季研究会议:蛋白质激酶
- 批准号:
3435131 - 财政年份:1991
- 资助金额:
$ 32.28万 - 项目类别:
CGMP-BINDING PHOSPHODIESTERASE: REGULATORY MECHANISMS
CGMP 结合磷酸二酯酶:调节机制
- 批准号:
3299350 - 财政年份:1989
- 资助金额:
$ 32.28万 - 项目类别:
相似国自然基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
- 批准号:81300507
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
P1082 - Revealing Mercer 5's Pulsar Population with Parkes
P1082 - 揭秘默瑟 5
- 批准号:
Local : csiro:P1082 - 财政年份:
- 资助金额:
$ 32.28万 - 项目类别:














{{item.name}}会员




